TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05670028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypotensive Drugs and/or Vasoactive Drugs
Description: To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensive Drugs and/or Vasoactive Drugs
Description: To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
Study: NCT05586672

Intervention type: DIAGNOSTIC_TEST
Intervention: ADI-R
Description: Passation of ADI-R scale

Intervention type: DIAGNOSTIC_TEST
Intervention: ADOS-2
Description: Passation of ADOS-2 scale

Intervention type: DIAGNOSTIC_TEST
Intervention: ADOS-2
Description: Passation of ADOS-2 scale

Intervention type: DIAGNOSTIC_TEST
Intervention: IDE
Description: Passation of IDE scale

Intervention type: DIAGNOSTIC_TEST
Intervention: IDE
Description: Passation of IDE scale

Intervention type: DIAGNOSTIC_TEST
Intervention: MSEL
Description: Passation of MSEL scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Dunn
Description: Passation of Dunn scale
Study: NCT05343234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tree different placebo drugs with tree different names and scheduled will be given
Study: NCT06296641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Needs navigation intervention
Description: The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
Study: NCT05764057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Study: NCT05292066

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine Tablets,
Description: Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin Tablets
Description: Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
Study: NCT04743960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Time-of-day of parenteral nutrition provision
Description: Parenteral nutrition will be provided during the nighttime followed by daytime.
Study: NCT05792592

Intervention type: DIAGNOSTIC_TEST
Intervention: IOS (Impulse Oscillometry)
Description: Small Airways Disease Assessment
Study: NCT05820555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed evening technology and digital media use (tablet use)
Description: timing of children's evening tablet device use relative to bedtime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed evening technology and digital media use (tablet use)
Description: timing of children's evening tablet device use relative to bedtime
Study: NCT05273450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Information with Reinforcement
Description: The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
Study: NCT05967884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
Description: Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
Description: Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
Study: NCT05820555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no technology and digital media use (screen media use)
Description: no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
Study: NCT02772081

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LISA combination product (Curosurf+catheter CHF6440)
Description: Curosurf administration through brief insertion of a thin catheter into the trachea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curosurf through conventional administration (endotracheal tube)
Description: Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
Study: NCT05451862

Intervention type: DEVICE
Group type: OTHER
Intervention: Holmium-166 treatment
Description: Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.

Intervention type: DEVICE
Group type: OTHER
Intervention: Holmium-166 work-up
Description: Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
Study: NCT05164042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD19 CAR-T cells
Description: infusion of allogeneic CD19 CAR-T cells
Study: NCT05312398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: III LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line
Study: NCT06304506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross sectional study
Description: Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross sectional study
Description: Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
Study: NCT06201117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preparatory information for ICU stay
Description: Preparatory information for ICU stay after cardiac surgery via 12-minute digital media

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual information
Description: Preoperative information that is given to patients before having cardiac surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual information
Description: Preoperative information that is given to patients before having cardiac surgery
Study: NCT05153044

Intervention type: OTHER
Group type: OTHER
Intervention: severe acute respiratory syndrome CoV-2 serology
Description: diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: severe acute respiratory syndrome CoV-2 serology
Description: diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: severe acute respiratory syndrome CoV-2 serology
Description: diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
Study: NCT04899414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
Description: Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
Study: NCT06120036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kybella
Description: Injection into the cutaneous Neurofibromas lesion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asclera
Description: Injection into the cutaneous Neurofibromas lesion.
Study: NCT05766475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ROSE Program: In Person
Description: In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE Program: Virtual
Description: Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
Study: NCT05160831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
Study: NCT06304506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross sectional study
Description: Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
Study: NCT05610956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional treatment
Description: conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
Study: NCT06055816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar and Envafolimab
Description: Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
Study: NCT05552105

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
Study: NCT05077670

Intervention type: PROCEDURE
Intervention: Pulmonary vein electrical isolation
Description: Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
Study: NCT06441292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-assisted
Description: utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-AI-assisted
Description: undergo standard prostate biopsy procedures without additional technological assistance
Study: NCT06349135

Intervention type: PROCEDURE
Intervention: Open Reduction & Internal Fixation
Description: Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.

Intervention type: PROCEDURE
Intervention: Open Reduction & Internal Fixation
Description: Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
Study: NCT04186247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
Study: NCT05364736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland barley β-glucan dietary supplement
Description: 100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: Placebo with a similar appearance and taste to highland barley β-glucan supplement
Study: NCT05077670

Intervention type: DEVICE
Intervention: Atrial substrate mapping
Description: Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
Study: NCT06375785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago-based (slow rhythmic) exercise group
Description: Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSVT BIG-based (large amplitude) exercise group
Description: Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking
Study: NCT05569876

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled hypoglycemic state
Description: Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
Study: NCT06183879

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)
Description: Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)
Description: Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
Study: NCT06578143

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
Study: NCT05547529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
Description: Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
Description: Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
Study: NCT02962804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
Study: NCT05009602

Intervention type: DIAGNOSTIC_TEST
Intervention: Toe Brachial Pressure Index (TBPI)
Description: TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ankle Brachial Pressure Index (ABPI)
Description: A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Ankle Brachial Pressure Index (ABPI)
Description: A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Audible handheld Doppler
Description: Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual handheld Doppler
Description: Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Podiatry Ankle Duplex scan (PAD-scan)
Description: Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only.
Study: NCT05823844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
Study: NCT05229796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg Tab
Description: The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg Tab
Description: The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
Study: NCT06578143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synbiotics
Description: Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.